valtocohcp.com valid

VALTOCO (diazepam nasal spray) CIV

VALTOCO is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. See information about VALTOCO for HCPs, including full [Prescribing Information](https://www.valtoco.com/PI), Boxed Warning, and [Instructions for Use](https://valtoco.com/VALTOCO_Instructions_For_Use.pdf).

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-24T11:42:32.633Z. Cached copy · Source on valtocohcp.com

# VALTOCO (diazepam nasal spray) CIV

> VALTOCO is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. See information about VALTOCO for HCPs, including full [Prescribing Information](https://www.valtoco.com/PI), Boxed Warning, and [Instructions for Use](https://valtoco.com/VALTOCO_Instructions_For_Use.pdf).

> This site is intended for Health Care Professionals. For the Patient version of the site please visit https://www.valtoco.com/.


## Indication
VALTOCO (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older.

## IMPORTANT SAFETY INFORMATION

> **WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS**
> - **Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.**
> - **The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.**
> - **The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.**

**Contraindications:** VALTOCO is contraindicated in patients with:
- Hypersensitivity to diazepam
- Acute narrow-angle glaucoma

**Central Nervous System (CNS) Depression**

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, h
…

Related sites

Explore similar publishers →

Similar publisher descriptions and documentation. Similarity does not imply affiliation or equivalent capabilities.

Machine-readable: GET /v1/resolve?q=valtocohcp.com · GET /v1/domain/valtocohcp.com · this page as Accept: application/json or text/markdown · MCP lookup_domain

Automatically discovered from public files. Inclusion does not imply endorsement or publisher participation.

Claim my listing on Agent Web Map for valtocohcp.com:
1. POST https://agentwebmap.com/v1/sites/valtocohcp.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://valtocohcp.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/valtocohcp.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/valtocohcp.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory.